Alkermes plc. (ALKS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-02-12

Key Insights

Alkermes entered into a $1.525 billion term loan credit facility to fund its acquisition of Avadel Pharmaceuticals.
The credit facility includes a $750 million term loan A and a $775 million term loan B, with maturities in 2031.
The acquisition of Avadel Pharmaceuticals, a wholly owned subsidiary, suggests Alkermes is diversifying its product portfolio and expanding its market reach.

Want the newest filings?

This analysis covers the filing from 2026-02-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-12

Alkermes plc provided preliminary, unaudited revenue estimates for the year ended December 31, 2025, indicating potential growth or decline that investors should monitor.
The company is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026, which could provide additional insights into the company's financial performance and outlook.
Investors should review the corporate presentation, when available, for more details on the company's financial results and any potential impact on the stock price.

Other reports for Alkermes plc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.